Show Summary Details
Page of

Vaccination against myeloid leukaemias using newly defined antigens 

Vaccination against myeloid leukaemias using newly defined antigens
Chapter:
Vaccination against myeloid leukaemias using newly defined antigens
Author(s):

Susanne Hofmann

, Ghazala Khan

, Viktoriya Boncheva

, Jochen Greiner

, and Barbara-ann Guinn

DOI:
10.1093/med/9780199676866.003.0019
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 06 August 2020

First complete remission rates are high in patients with acute myeloid leukaemia (AML), with some variation depending on the presence of specific cytogenetic and molecular aberrations. However, the remission is often not long lasting and relapse occurs after standard chemotherapy within two years. Besides chemotherapy, non-specific immunotherapy in the form of allogeneic haematopoietic stem cell transplantation (HSCT) is an integral part of consolidation and salvage therapy in the treatment of AML. A large number of leukaemia-associated antigens (LAAs) that can act as potential targets for specific immunotherapy have been identified, and the number is still increasing. To date, several of these antigens are being utilized in clinical vaccination trials, either as active specific immunotherapy in form of peptide vaccination or as passive specific immunotherapy as adoptive cell therapies. This chapter reviews the role of newly defined LAAs as well as the results of already performed clinical vaccination trials with known LAAs.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.